Back to results
US 12,680,090 B1Granted
Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and modified biomolecules
AssigneeTeledyne FLIR Defense, Inc.
InventorsDavid Wilson, Jennifer L. Poole, Jeremy P. Walker
Life of this patent
Estimating the term…
Abstract
Pharmaceutical formulations that can include at least one genetically modified OPH enzyme are provided. Methods for treating chemical warfare agent exposure are also provided. Modified biomolecules are also provided.
Claims10
A pharmaceutical formulation comprising a composition and a pharmaceutically-acceptable buffer, wherein the composition comprises:
- a first organophosphorus hydrolase (OPH) protein:polymer conjugate that comprises:
- at least a first genetically-modified OPH YT protein;
- and
- at least a first polymer produced via controlled radical polymerization from a molecular initiator, wherein the molecular initiator is conjugated to the first genetically-modified OPH YT protein and the polymer comprises polyethylene glycol methyl-ethyl methacrylate (PEGMA) chain;
- wherein an in vivo kcat/km of the protein:polymer conjugate is >1×107 for at least one G-series chemical warfare agent.
2 more elements
A pharmaceutical formulation comprising a composition and a pharmaceutically-acceptable buffer, wherein the composition comprises:
- a first organophosphorus hydrolase (OPH) protein:polymer conjugate that comprises:
- at least a first genetically-modified OPH YT protein;
- and
- at least a first polymer conjugated thereto, the polymer comprising a polyethylene glycol methyl-ethyl methacrylate (PEGMA) chain;
- wherein an in vivo kcat/km of the protein:polymer conjugate is >1×107 for at least one G-series chemical warfare agent.
2 more elements
Dependencies are inferred from the claim text.